Edgewise Therapeutics (EWTX) Cash from Investing Activities (2020 - 2026)

Edgewise Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 94.46% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$74.3 million (down 158.22% YoY) and the FY2025 annual result came in at -$32.8 million, up 82.24% from the prior year.
• Cash from Investing Activities slipped to $2.4 million in Q1 2026 per EWTX's latest filing, from $49.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $49.8 million in Q4 2025 and troughed at -$268.3 million in Q1 2024.
• A 5-year average of -$10.7 million and a median of $23.4 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 7582.61% in 2023, then plunged 647.1% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$75.6 million in 2022, then soared by 135.69% to $27.0 million in 2023, then dropped by 22.46% to $20.9 million in 2024, then soared by 137.85% to $49.8 million in 2025, then slumped by 95.11% to $2.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $2.4 million, $49.8 million, and $35.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.